Bristol-Myers Squibb Company Statement On Muraglitazar, An Investigational Oral Treatment For Type 2 Diabetes

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- As previously disclosed, on October 18, 2005, the U.S. Food and Drug Administration (FDA) issued an approvable letter for muraglitazar, Bristol-Myers Squibb Company's investigational oral medicine for the treatment of type 2 diabetes. The FDA requested additional information from ongoing clinical trials to more fully address the cardiovascular safety profile of muraglitazar. We and our partner, Merck & Co., Inc., (Merck) have determined that to receive regulatory approval and to achieve commercial success, additional studies may be required because the ongoing trials were not designed to answer questions raised by the FDA. The additional studies could take approximately five years to complete.

In addition, Bristol-Myers Squibb has agreed to begin discussions with Merck to terminate the collaborative agreement.

Bristol-Myers Squibb will continue discussions with the FDA and will consider a range of options including conducting additional studies or terminating further development of muraglitazar.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 regarding a product in development that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainty of the success of the research and development activities; decisions by regulatory authorities regarding whether and when to approve any new drug application for a product candidate that may result from the research, as well as their decisions regarding labeling and other matters that could affect the commercial potential of such product candidate; and competitive developments. A further list and description of risks and uncertainties can be found in the Bristol-Myers Squibb's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and in its reports on Form 10-Q and Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Visit Bristol-Myers Squibb on the World Wide Web at www.bms.com

Bristol-Myers Squibb Company

CONTACT: Media - David M. Rosen, +1-609-252-5675, pager, 1-866-308-4484,david.m.rosen@bms.com, or Tony Plohoros, +1-609-252-7938, cell,+1-908-591-2839 tony.plohoros@bms.com, Investors - John Elicker,+1-212-546-3775, john.elicker@bms.com, all of Bristol-Myers Squibb Company

Back to news